Kura Oncology Inc (KURA)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014144)
◆英語タイトル:Kura Oncology Inc (KURA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014144
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:46
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Kura Oncology Inc (Kura Oncology) is a clinical-stage biopharmaceutical company which discovers and develops therapeutics for the treatment of solid tumors and blood cancers. Its lead drug candidate, Tipifarnib, an inhibitor of protein farnesylation, is a small molecule that targets oncogenes or signaling pathways that drive cancer growth. The company’s pipeline product portfolio includes Tipifarnib – HRAS, Tipifarnib – PTCL, Tipifarnib – MDS, Tipifarnib- CMML and others. Kura Oncology’s phase I and pre-clinical stage products are KO-947, a small molecule inhibitor of extracellular-signal-regulated kinases 1 and 2 (ERK1/2) and KO-539 inhibitor program inhibits the interaction between the proteins menin and MLL for the treatment of MLL-rearranged (MML-r) leukemias. It targets therapeutic areas which include T-cell lymphoma, melanoma, lung and pancreatic cancers, mixed lineage leukemia and other cancers. Kura Oncology is headquartered in La Jolla, California, the US.

Kura Oncology Inc (KURA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Kura Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Kura Oncology Acquires Patent Rights of ERK Program from Araxes Pharma 11
Venture Financing 12
Kura Oncology Raises USD91.69 Million in Venture Financing 12
Merger 13
Kura Oncology and Zeta Acquisition Complete Reverse Merger Transaction 13
Licensing Agreements 14
Kura Oncology Amends Licensing Agreement with Janssen Pharma 14
Kura Oncology Amends its Licensing Agreement with University of Michigan 16
Equity Offering 17
Kura Oncology Prices Public Offering of Shares for USD50 Million 17
Kura Oncology Raises USD50 Million in Public Offering of Shares 19
Kura Oncology Raises USD60 Million in Private Placement of Common Stock 21
Kura Oncology Inc – Key Competitors 23
Kura Oncology Inc – Key Employees 24
Kura Oncology Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 07, 2017: Kura Oncology Reports Second Quarter 2017 Financial Results 26
May 15, 2017: Kura Oncology Reports First Quarter 2017 Operational and Financial Results 27
Mar 14, 2017: Kura Oncology Reports Fourth Quarter and Full Year 2016 Operational and Financial Results 29
Nov 07, 2016: Kura Oncology Reports Third Quarter 2016 Financial Results 30
Aug 10, 2016: Kura Oncology Reports Second Quarter 2016 Financial Results 31
May 11, 2016: Kura Oncology Reports First Quarter 2016 Financial Results 32
Mar 17, 2016: Kura Oncology Reports Fourth Quarter and Full Year 2015 Operational and Financial Results 33
Corporate Communications 35
Jan 03, 2017: Kura Oncology Appoints Steven Stein, M.D. to Board of Directors 35
Product News 36
01/04/2017: Kura Oncology Nominates KO-539 as Development Candidate for Menin-MLL Inhibitor Program 36
Clinical Trials 37
Apr 07, 2017: Kura Oncology Doses First Patient in Phase 1 Trial of ERK Inhibitor KO-947 37
Apr 05, 2017: Kura Oncology Presents Preclinical Data Demonstrating Significant Anti-Tumor Activity of KO-947 38
Apr 05, 2017: Kura Oncology Presents Preclinical Data on KO-539 at the American Association for Cancer Research Annual Meeting 2017 39
Mar 29, 2017: Kura Oncology to Present Preclinical Data on KO-539 at AACR Annual Meeting 2017 40
Mar 29, 2017: Kura Oncology to Present Preclinical Data on KO-947 at AACR Annual Meeting 2017 41
Jan 04, 2017: Kura Oncology Receives FDA Clearance to Proceed with Clinical Trial for ERK Inhibitor KO-947 42
Dec 01, 2016: Kura Oncology Presents Data on Menin-MLL Inhibitor Program at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 43
Dec 01, 2016: Kura Oncology Presents Preclinical Data on KO-947 the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 44
Nov 15, 2016: Kura Oncology to Present Preclinical Data on Pipeline Programs at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Kura Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Kura Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Kura Oncology Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kura Oncology Acquires Patent Rights of ERK Program from Araxes Pharma 11
Kura Oncology Raises USD91.69 Million in Venture Financing 12
Kura Oncology and Zeta Acquisition Complete Reverse Merger Transaction 13
Kura Oncology Amends Licensing Agreement with Janssen Pharma 14
Kura Oncology Amends its Licensing Agreement with University of Michigan 16
Kura Oncology Prices Public Offering of Shares for USD50 Million 17
Kura Oncology Raises USD50 Million in Public Offering of Shares 19
Kura Oncology Raises USD60 Million in Private Placement of Common Stock 21
Kura Oncology Inc, Key Competitors 23
Kura Oncology Inc, Key Employees 24
Kura Oncology Inc, Other Locations 25

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Kura Oncology Inc (KURA)-製薬・医療分野:企業M&A・提携分析(Kura Oncology Inc (KURA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆